Improved halogenated oils for hepatosplenography.

J. Gershon-Cohen,J. Mcclendon

1956-09-01

Abstract:

What problem does this paper attempt to address?

Metronomic Chemotherapy: Anti-Tumor Pathways and Combination with Immune Checkpoint Inhibitors

Elena Muraro,Lorenzo Vinante,Elisabetta Fratta,Alessandra Bearz,Daniela Höfler,Agostino Steffan,Lorena Baboci

DOI: https://doi.org/10.3390/cancers15092471

2023-04-27

Cancers

Abstract:Increasing evidence pinpoints metronomic chemotherapy, a frequent and low dose drug administration with no prolonged drug-free intervals, as a potential tool to fight certain types of cancers. The primary identified targets of metronomic chemotherapy were the tumor endothelial cells involved in angiogenesis. After this, metronomic chemotherapy has been shown to efficiently target the heterogeneous population of tumor cells and, more importantly, elicit the innate and adaptive immune system reverting the "cold" to "hot" tumor immunologic phenotype. Although metronomic chemotherapy is primarily used in the context of a palliative setting, with the development of new immunotherapeutic drugs, a synergistic therapeutic role of the combined metronomic chemotherapy and immune checkpoint inhibitors has emerged at both the preclinical and clinical levels. However, some aspects, such as the dose and the most effective scheduling, still remain unknown and need further investigation. Here, we summarize what is currently known of the underlying anti-tumor effects of the metronomic chemotherapy, the importance of the optimal therapeutic dose and time-exposure, and the potential therapeutic effect of the combined administration of metronomic chemotherapy with checkpoint inhibitors in preclinical and clinical settings.

oncology
Current research status of metronomic chemotherapy in combination treatment of breast cancer

Jiaxuan Liu,Maiyue He,Zijing Wang,Qiao Li,Binghe Xu

DOI: https://doi.org/10.1159/000526481

2022-08-20

Oncology Research and Treatment

Abstract:Background: Metronomic chemotherapy (MCT), termed sustained low-dose administration with minimal toxicity, is a new modality of conventional chemotherapy, a verified therapy alternative, and has acquired significant recognition and interest in oncology. Numerous clinical trials of MCT in combination with other treatments, including targeted therapies, biologics, and endocrine therapy, are in progress to obtain better results. Summary: We systematically reviewed the most recent clinical data from Pubmed/Medline, ClinicalTrials.gov, and the European Clinical Trials Database. We comprehensively described the clinical benefits of MCT in combination with other treatments in different molecular subtypes of breast cancer and assessed the feasibility of its adoption in varying phases of treatment. Key message: MCT, in combination with other therapeutic interventions, will fully exploit the benefits of this strategy, ushering in a new paradigm in oncology treatment and driving the transformation of cancer into a more manageable chronic disease using newly developed treatment approaches.

oncology
Effects of Air, Oxygen and 20 per cent Carbon Dioxide on the Rabbit during Surface Cooling Down to Cardiac Arrest

B. Broom

DOI: https://doi.org/10.1038/1991155A0

IF: 64.8

1963-09-21

Nature

Abstract:
Optimizing cancer therapy: a review of the multifaceted effects of metronomic chemotherapy

Oyku Yagmur Basar,Sawsan Mohammed,M. Walid Qoronfleh,Ahmet Acar

DOI: https://doi.org/10.3389/fcell.2024.1369597

IF: 5.5

2024-05-16

Frontiers in Cell and Developmental Biology

Abstract:Metronomic chemotherapy (MCT), characterized by the continuous administration of chemotherapeutics at a lower dose without prolonged drug-free periods, has garnered significant attention over the last 2 decades. Extensive evidence from both pre-clinical and clinical settings indicates that MCT induces distinct biological effects than the standard Maximum Tolerated Dose (MTD) chemotherapy. The low toxicity profile, reduced likelihood of inducing acquired therapeutic resistance, and low cost of MCT render it an attractive chemotherapeutic regimen option. One of the most prominent aspects of MCT is its anti-angiogenesis effects. It has been shown to stimulate the expression of anti-angiogenic molecules, thereby inhibiting angiogenesis. In addition, MCT has been shown to decrease the regulatory T-cell population and promote anti-tumor immune response through inducing dendritic cell maturation and increasing the number of cytotoxic T-cells. Combination therapies utilizing MCT along with oncolytic virotherapy, radiotherapy or other chemotherapeutic regimens have been studied extensively. This review provides an overview of the current status of MCT research and the established mechanisms of action of MCT treatment and also offers insights into potential avenues of development for MCT in the future.

cell biology,developmental biology
Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience

Cem Simsek,Ece Esin,Suayib Yalcin

DOI: https://doi.org/10.1155/2019/5483791

IF: 4.501

2019-03-20

Journal of Oncology

Abstract:Metronomic chemotherapy, continuous and dose-dense administration of chemotherapeutic drugs with lowered doses, is being evaluated for substituting, augmenting, or appending conventional maximum tolerated dose regimens, with preclinical and clinical studies for the past few decades. To date, the principle mechanisms of its action include impeding tumoral angiogenesis and modulation of hosts’ immune system, affecting directly tumor cells, their progenitors, and neighboring stromal cells. Its better toxicity profile, lower cost, and easier use are main advantages over conventional therapies. The evidence of metronomic chemotherapy for personalized medicine is growing, starting with unfit elderly patients and also for palliative treatment. The literature reviewed in this article mainly demonstrates that metronomic chemotherapy is advantageous for selected patients and for certain types of malignancies, which make it a promising therapeutic approach for filling in the gaps. More clinical studies are needed to establish a solidified role for metronomic chemotherapy with other treatment models in modern cancer management.

oncology
The Application of Metronomic Chemotherapy in the Treatment of Breast Cancerthe Application of Metronomic Chemotherapy in the Treatment of Breast Cancer

Marina Elena Cazzaniga,Nicoletta Cordani,Serena Capici,Viola Cogliati,Francesca Riva,Maria Grazia Cerrito

2012-01-01

Abstract:Metronomic chemotherapy is a very new form of chemotherapy that has been rising in popularity in recent years.In low-dosages with continuous administration,it could sustainably inhibits tumor angiogenesis,reduces tumor size,controls tumor growth,reduces toxicity and side-effects,improves efficacy and reduces drug resistance.In the clinical treatment of patients with metastatic breast cancer,it has had positive treatment responses.With changes in treatment patterns and constant updates,more relevant therapeutic mechanisms were found,metronomic therapy was no longer used in encompassing just metronomic chemotherapy,but also chemotherapy,radiotherapy,adjuvant endocrine therapy and related treatment modalities.This interview was aimed to summarized the application of metronomic chemotherapy in the treatment of breast cancer.
A Meta-Analysis of Combination Therapy Versus Single-Agent Therapy in Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: Results from Nine Randomized Phase III Trials

Liang Xu,Xiaobo Wu,Chun Hu,Zhiying Zhang,Le Zhang,Shujing Liang,Yingchun Xu,Fengchun Zhang

DOI: https://doi.org/10.2147/ott.s101423

IF: 4

2016-01-01

OncoTargets and Therapy

Abstract:Nowadays, the philosophy of treating metastatic breast cancer (MBC) is slowly evolving. Especially for the anthracycline- and taxane-pretreated MBC patients, no standard therapy exists in this setting. Whether to choose doublet agents or single agent as salvage treatment remains fiercely debated. Thus, we conducted a meta-analysis to resolve this problem. Databases including PubMed, EMBASE, and Cochrane library were searched for Phase III randomized clinical trials (published before August 2015) comparing the efficacy and adverse effects between the combination therapy and single-agent therapy in anthracycline- and taxane-pretreated MBC patients. The primary end point was the overall survival (OS), and the secondary end points were the progression-free survival (PFS), overall response rate (ORR), and grade 3 or 4 toxicities. The pooled hazard ratio (HR) and pooled risk ratio (RR) were used to evaluate the efficacy. Analyses were also performed to estimate the side effects and safety of both groups. In all, nine eligible randomized clinical trials were included in this meta-analysis. Improvements were proven in the doublet agents group on OS (HR 0.90, 95% confidence interval [CI] 0.84-0.96, P=0.002), PFS (HR 0.81, 95% CI 0.76-0.88, P<0.001), and ORR (RR 1.72, 95% CI 1.34-2.21, P<0.001). Notably, subgroup analysis failed to favor the targeted agent-based combination in terms of OS (HR 1.08, 95% CI 0.89-1.31, P=0.365), PFS (HR 1.09, 95% CI 0.88-1.35, P=0.433), and ORR (RR 1.60, 95% CI 0.69-3.71, P=0.278) compared with single agent. In addition, although more hematological and gastrointestinal toxicities were observed in the doublet agents group, they were acceptable and manageable. Taken together, when compared with single-agent therapy, doublet agents should be considered a treatment option because of the superior efficacy and the manageable safety profile for the prior anthracycline- and taxane-treated MBC patients.
Nanoformulations-Based Metronomic Chemotherapy: Mechanism, Challenges, Recent Advances, and Future Perspectives

Vijay Kumar Panthi,Kamal Dua,Sachin Kumar Singh,Gaurav Gupta,Keshav Raj Paudel,Philip M. Hansbro

DOI: https://doi.org/10.3390/pharmaceutics15041192

IF: 6.525

2023-04-09

Pharmaceutics

Abstract:Cancer-related death is a significant health and economic burden worldwide, and some conventional chemotherapy is associated with limited effectiveness in completely curing various cancers, severe adverse effects, and destruction of healthy cells. To overcome the complications associated with conventional treatment, metronomic chemotherapy (MCT) is extensively suggested. In this review, we aim to highlight the importance of MCT over conventional chemotherapeutic approach with emphasis on nanoformulations-based MCT, their mechanism, challenges, recent advances, and future perspectives. Nanoformulations-based MCT revealed remarkable antitumor activity in both preclinical and clinical settings. For example, the metronomic scheduling of oxaliplatin-loaded nanoemulsion and polyethylene glycol-coated stealth nanoparticles incorporating paclitaxel were proven very effective in tumor-bearing mice and rats, respectively. Additionally, several clinical studies have demonstrated the benefit of MCT with acceptable tolerance. Moreover, metronomic might be a promising treatment strategy for improving cancer care in low- and middle-income nations. However, an appropriate alternative to a metronomic regimen for an individual ailment, suitable combinational delivery and scheduling, and predictive biomarkers are certain parts that remain unanswered. Further clinical-based comparative research studies are mandatory to be performed before entailing this treatment modality in clinical practice as alternative maintenance therapy or in place of transferring to therapeutic management.

pharmacology & pharmacy
Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?

Rafael Caparica,Claudia De Angelis,Ângelo Fêde,Gustavo Werutsky,Evandro de Azambuja

DOI: https://doi.org/10.1080/14737140.2020.1782200

2020-06-30

Expert Review of Anticancer Therapy

Abstract:Metronomic chemotherapy exerts its effects via inhibition of angiogenesis, immune modulation of the tumoral stroma, induction of senescence and apoptosis of tumor cells. Due to its favorable toxicity profile and its oral administration, metronomic chemotherapy arises as a promising alternative to be combined with endocrine therapy for the treatment of patients with luminal breast cancer.The present manuscript reviews the rationale supporting the combination of metronomic chemotherapy and endocrine therapy, discussing the studies that evaluated this regimen in the treatment of early-stage and metastatic breast cancer patients. Finally, we conclude by providing an expert opinion on the current role and perspectives for the combination of metronomic chemotherapy and endocrine therapy in the management of patients with luminal breast cancer.Retrospective series and early-phase clinical trials have shown promising signs of activity and a favorable toxicity profile with this regimen, which warrants further investigation as a treatment option for luminal breast cancer patients.

oncology
Effects of clonidine on operant behavior and electric shock titration in the squirrel monkey: Effects of α2-adrenoreceptor antagonism

J. Mckearney

DOI: https://doi.org/10.1016/0028-3908(83)90102-8

IF: 5.273

1983-06-01

Neuropharmacology

Abstract:
Advances In Combination Of Antiangiogenic Agents Targeting Vegf-Binding And Conventional Chemotherapy And Radiation For Cancer Treatment

Li-Song Teng,Ke-Tao Jin,Kui-Feng He,Hao-Hao Wang,Jiang Cao,De-Cao Yu

DOI: https://doi.org/10.1016/S1726-4901(10)70062-9

2010-01-01

Abstract:Despite great efforts and resources being devoted to treatment, the incidence and mortality of numerous cancers have not decreased in recent decades. This is a result of the resistance of cancer cells to chemotherapeutic agents and radiotherapy. The development of antiangiogenic agents that target vascular endothelial growth factor (VEGF) provides a new option for treatment of cancer. Major advances have been achieved with cancer therapy based on antiangiogenic VEGF-targeted agents in the past few years, and some of the recently approved therapies are now being used in daily clinical practice. A further challenge is finding a more efficacious combination of antiangiogenic VEGF-targeted therapies and conventional radio- and chemotherapies. This review outlines the current preclinical and clinical cancer treatments using optimized combinations of antiangiogenic VEGF-targeted agents and conventional radiochemotherapy and highlights that better scheduling for the combination of radiochemotherapy and antiangiogenic VEGF-targeted agents should be developed to achieve better treatment outcomes. [J Chin Med Assoc 2010;73(6):281-288]
Metronomic Chemotherapy for Metastatic Breast Cancer

Slavomir Krajnak,Marco J Battista,Annette Hasenburg,Marcus Schmidt,Marco J. Battista

DOI: https://doi.org/10.1159/000520236

2021-11-18

Oncology Research and Treatment

Abstract:Background: As disease control and quality of life play a leading role in metastatic breast cancer (MBC), metronomic chemotherapy (MCT) is gaining popularity alongside conventional chemotherapy (CCT) and targeted therapies. Summary: MCT, defined as continuous administration of low-dose chemotherapeutic agents, is accepted as a therapy that exerts its effects via immunomodulation, anti-angiogenesis and direct cytotoxic effects. Oral administration of MCT is safe, easy to handle, and allows for flexible drug dosing. Dose accumulations associated with non-tolerable side effects are rare, so the medication can be administered for longer periods of time. Patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic disease resistant to endocrine-based therapy and not requiring rapid tumor response are generally suitable for MCT. However, MCT may also be promising in patients with triple-negative and HER2-positive tumors without aggressive disease who prefer a lower toxicity profile compared to CCT. The most commonly used agents are cyclophosphamide (CTX), methotrexate (MTX), capecitabine (CAPE), and vinorelbine (VRL), whereby a combination of agents is frequently applied. Key Messages: Based on the growing body of evidence, MCT can be considered as a suitable treatment option in selected MBC patients. Nevertheless, there is an urgent need for randomized controlled trials comparing MCT with CCT, but also with best supportive care. Due to the multimodal mechanisms of action, the combination with targeted and immunological therapies may represent a new promising approach for the treatment of MBC.

oncology
Tumor endothelial cells as a potential target of metronomic chemotherapy

Ji Yoon Kim,Young-Myeong Kim

DOI: https://doi.org/10.1007/s12272-018-01102-z

2019-01-01

Archives of Pharmacal Research

Abstract:Drug resistance and toxic side effects are major therapeutic hurdles affecting cancer patients receiving conventional chemotherapy based on the maximum tolerated dose. Metronomic chemotherapy (MCT), a new therapeutic approach developed to avoid these problems generally, consists of the continuous administration of low-dose cytotoxic agents without extended intervals. This therapy targets the tumor microenvironment, rather than exerting a direct effect on tumor cells. As a result, the MCT regimen functionally impairs tumor endothelial cells and circulating endothelial progenitor cells, leading to tumor dormancy via anti-angiogenesis. Over the past 10 years, several studies have highlighted the impact of MCT on the tumor microenvironment and angiogenesis and demonstrated its potential as a switch from the pro-angiogenic to the anti-angiogenic state. However, the mechanisms of action are still obscure. Here, we systematically review the evidence regarding the anti-angiogenic potential of MCT as a crucial determinant of tumor dormancy and cancer treatment.

pharmacology & pharmacy,chemistry, medicinal
Metronomic Chemotherapy in Oral Cancer: A Review

Sathya Sethuraman,Karthikeyan Ramalingam

DOI: https://doi.org/10.7759/cureus.49825

2023-12-02

Cureus

Abstract:Treatment of locally advanced oral cancer requires multidisciplinary care, including surgery, radiotherapy, and chemotherapy, which varies based on the stage of the disease, site of involvement, and surgical access. Oral cancer usually presents with an increased recurrence rate and potential for distant metastatic spread. It confers a poor prognosis with a 50% mortality rate after five years. Oral metronomic chemotherapy aims to achieve higher patient compliance due to its ease of administration, lower dosage, and lesser side effects than conventional IV regimens of platinum-based drugs. In this review, we have summarized the relevant literature to benefit the readers regarding the potential application of metronomic therapy in the management of oral cancer.
Nanoparticle-mediated metronomic chemotherapy in cancer: A paradigm of precision and persistence

Apoorv Kirti,Faizan Zarreen Simnani,Snehasmita Jena,Sudakshya S Lenka,Chethana Kalalpitiya,Shaikh Sheeran Naser,Dibyangshee Singh,Anmol Choudhury,Rudra Narayan Sahu,Anu Yadav,Adrija Sinha,Aditya Nandi,Pritam Kumar Panda,Nagendra Kumar Kaushik,Mrutyunjay Suar,Suresh K Verma

DOI: https://doi.org/10.1016/j.canlet.2024.216990

2024-07-10

Abstract:Current methods of cancer therapy have demonstrated enormous potential in tumor inhibition. However, a high dosage regimen of chemotherapy results in various complications which affect the normal body cells. Tumor cells also develop resistance against the prescribed drugs in the whole treatment regimen increasing the risk of cancer relapse. Metronomic chemotherapy is a modern treatment method that involves administering drugs at low doses continuously, allowing the drug sufficient time to take its effect. This method ensures that the toxicity of the drugs is to a minimum in comparison to conventional chemotherapy. Nanoparticles have shown efficacy in delivering drugs to the tumor cells in various cancer therapies. Combining nanoparticles with metronomic chemotherapy can yield better treatment results. This combination stimulates the immune system, improving cancer cells recognition by immune cells. Evidence from clinical and pre-clinical trials supports the use of metronomic delivery for drug-loaded nanoparticles. This review focuses on the functionalization of nanoparticles for improved drug delivery and inhibition of tumor growth. It emphasizes the mechanisms of metronomic chemotherapy and its conjunction with nanotechnology. Additionally, it explores tumor progression and the current methods of chemotherapy. The challenges associated with nano-based metronomic chemotherapy are outlined, paving the way for prospects in this dynamic field.
Synergy Between Low Dose Metronomic Chemotherapy and the pH-centered Approach Against Cancer

Tomas Koltai,Rosa A. Cardone,Stephan J. Reshkin,Koltai,Cardone,Reshkin

DOI: https://doi.org/10.3390/ijms20215438

IF: 5.6

2019-10-31

International Journal of Molecular Sciences

Abstract:Low dose metronomic chemotherapy (MC) is becoming a mainstream treatment for cancer in veterinary medicine. Its mechanism of action is anti-angiogenesis by lowering vascular endothelial growth factor (VEGF) and increasing trombospondin-1 (TSP1). It has also been adopted as a compassionate treatment in very advanced human cancer. However, one of the main limitations of this therapy is its short-term effectiveness: 6 to 12 months, after which resistance develops. pH-centered cancer treatment (pHT) has been proposed as a complementary therapy in cancer, but it has not been adopted or tested as a mainstream protocol, in spite of existing evidence of its advantages and benefits. Many of the factors directly or indirectly involved in MC and anti-angiogenic treatment resistance are appropriately antagonized by pHT. This led to the testing of an association between these two treatments. Preliminary evidence indicates that the association of MC and pHT has the ability to reduce anti-angiogenic treatment limitations and develop synergistic anti-cancer effects. This review will describe each of these treatments and will analyze the fundamentals of their synergy.

biochemistry & molecular biology,chemistry, multidisciplinary
Dose-dependent bidirectional pharmacological effects of vinorelbine-based metronomic combination chemotherapy on tumor growth and metastasis and mechanisms in melanoma mouse model

Hua Liu,Qiaowei Zheng,Min Li,Jianrong Kou,Junsong Wei,Weiyi Feng

DOI: https://doi.org/10.1111/fcp.12939

Abstract:Background: There is evidence that the empirical setting of doses and schedules of antineoplastic agents in metronomic chemotherapy (MC) might lead to undesirable outcomes, such as promoting tumor growth or metastasis at certain low doses. However, details about the dose effect of antineoplastic agents in MC have not been fully known yet. Objectives: Vinorelbine combined with cisplatin or fluorouracil (VNR/CDDP or VNR/FU) was selected to investigate its effects on tumor growth or metastasis as well as mechanisms. Methods: Experimental techniques, including immunohistochemistry, western blot, immunofluorescence, and flow cytometry, were used to explore the mechanisms, along with cell proliferation, apoptosis, migration, and invasion. Results: The results showed that VNR/CDDP or VNR/FU promoted tumor growth and metastasis at low doses and inhibited them at high ones. Except that expressions of apoptotic proteins were elevated at both low and high doses, low-dose treatments enhanced angiogenesis and promoted the mobilization and recruitment of myeloid-derived suppressor cells (MDSCs), while high-dose treatments reversed these effects. Additionally, low concentrations of VNR/CDDP or VNR/FU stimulated tumor cell functions such as anti-apoptosis, migration, and invasion, but high concentrations only suppressed cell proliferation and increased apoptosis. Conclusion: This study elucidated a bidirectional action mode regulated by multiple mechanisms at different doses in MC and also highlighted the risks of low-dose metronomic administration of antineoplastic agents in the clinic. More preclinical and clinical studies focusing on the dose-effect of metronomic regimens are urgently needed because an effective therapeutic regimen should be an optimal setting of drugs, doses, schedules, or combinations.
The future of metronomic chemotherapy: experimental and computational approaches of drug repurposing

Yousef A. Abdelrady,Hayam S. Thabet,Ahmed M. Sayed

DOI: https://doi.org/10.1007/s43440-024-00662-w

2024-10-21

Pharmacological Reports

Abstract:Metronomic chemotherapy (MC), long-term continuous administration of anticancer drugs, is gaining attention as an alternative to the traditional maximum tolerated dose (MTD) chemotherapy. By combining MC with other treatments, the therapeutic efficacy is enhanced while minimizing toxicity. MC employs multiple mechanisms, making it a versatile approach against various cancers. However, drug resistance limits the long-term effectiveness of MC, necessitating ongoing development of anticancer drugs. Traditional drug discovery is lengthy and costly due to processes like target protein identification, virtual screening, lead optimization, and safety and efficacy evaluations. Drug repurposing (DR), which screens FDA-approved drugs for new uses, is emerging as a cost-effective alternative. Both experimental and computational methods, such as protein binding assays, in vitro cytotoxicity tests, structure-based screening, and several types of association analyses (Similarity-Based, Network-Based, and Target Gene), along with retrospective clinical analyses, are employed for virtual screening. This review covers the mechanisms of MC, its application in various cancers, DR strategies, examples of repurposed drugs, and the associated challenges and future directions.

pharmacology & pharmacy
Promotion of tumor angiogenesis and growth induced by low-dose antineoplastic agents via bone-marrow-derived cells in tumor tissues

Huining You,Peipei Zhao,Xue Zhao,Qiaowei Zheng,Wenbing Ma,Kai Cheng,Min Li,Jianrong Kou,Weiyi Feng

DOI: https://doi.org/10.3389/fphar.2024.1414832

IF: 5.6

2024-07-26

Frontiers in Pharmacology

Abstract:Background: More research is needed to solidify the basis for reasonable metronomic chemotherapy regimens due to the inconsistent clinical outcomes from studies on metronomic chemotherapy with antineoplastic agents, along with signs of a nonlinear dose–response relationship at low doses. The present study therefore explored the dose–response relationships of representative antineoplastic agents in low dose ranges and their underlying mechanisms. Methods: Cyclophosphamide (CPA) and 5-fluorouracil (5-Fu) were employed to observe the effects of the frequent administration of low-dose antineoplastic agents on tumor growth, tumor angiogenesis, and bone-marrow-derived cell (BMDC) mobilization in mouse models. The effects of antineoplastic agents on tumor and endothelial cell functions with or without BMDCs were analyzed in vitro . Results: Tumor growth and metastasis were significantly promoted after the administration of CPA or 5-Fu at certain low dose ranges, and were accompanied by enhanced tumor angiogenesis and proangiogenic factor expression in tumor tissues, increased proangiogenic BMDC release in the circulating blood, and augmented proangiogenic BMDC retention in tumor tissues. Low concentrations of CPA or 5-Fu were found to significantly promote tumor cell migration and invasion, and enhance BMDC adhesion to endothelial cells in vitro . Conclusion: These results suggest that there are risks in empirical metronomic chemotherapy using low-dose antineoplastic agents and the optimal dosage and administration schedule of antineoplastic agents need to be determined through further research.

pharmacology & pharmacy
Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers

Luana Schito,Sergio Rey,Ping Xu,Shan Man,William Cruz‐Muñoz,Robert S Kerbel

DOI: https://doi.org/10.15252/emmm.201911416

2020-07-20

EMBO Molecular Medicine

Abstract:<p>Conventional maximum‐tolerated dose (MTD) chemotherapy relies on periodic, massive cancer cell ablation events followed by treatment‐free intermissions, stereotypically resulting in resistance, relapse, and mortality. Furthermore, MTD chemotherapy can promote metastatic dissemination via activation of a transcriptional program dependent on hypoxia‐inducible factor (HIF)‐1α and (HIF)‐2α (hereafter referred to as HIFα). Instead, frequent low‐dose metronomic (LDM) chemotherapy displays less adverse effects while preserving significant pre‐clinical anticancer activity. Consequently, we hereby compared the effect of MTD or LDM chemotherapy upon HIFα in models of advanced, metastatic colon and breast cancer. Our results revealed that LDM chemotherapy could offset paralog‐specific, MTD‐dependent HIFα induction in colon cancers disseminating to the liver and lungs, while limiting HIFα and hypoxia in breast cancer lung metastases. Moreover, we assessed the translational significance of HIFα activity in colorectal and breast TCGA/microarray data, by developing two compact, 11‐gene transcriptomic signatures allowing the stratification/identification of patients likely to benefit from LDM and/or HIFα‐targeting therapies. Altogether, these results suggest LDM chemotherapy as a potential maintenance strategy to stave off HIFα induction within the intra‐metastatic tumor microenvironment.</p>

medicine, research & experimental

Improved halogenated oils for hepatosplenography.

Metronomic Chemotherapy: Anti-Tumor Pathways and Combination with Immune Checkpoint Inhibitors

Current research status of metronomic chemotherapy in combination treatment of breast cancer

Effects of Air, Oxygen and 20 per cent Carbon Dioxide on the Rabbit during Surface Cooling Down to Cardiac Arrest

Optimizing cancer therapy: a review of the multifaceted effects of metronomic chemotherapy

Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience

The Application of Metronomic Chemotherapy in the Treatment of Breast Cancerthe Application of Metronomic Chemotherapy in the Treatment of Breast Cancer

A Meta-Analysis of Combination Therapy Versus Single-Agent Therapy in Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: Results from Nine Randomized Phase III Trials

Nanoformulations-Based Metronomic Chemotherapy: Mechanism, Challenges, Recent Advances, and Future Perspectives

Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?

Effects of clonidine on operant behavior and electric shock titration in the squirrel monkey: Effects of α2-adrenoreceptor antagonism

Advances In Combination Of Antiangiogenic Agents Targeting Vegf-Binding And Conventional Chemotherapy And Radiation For Cancer Treatment

Metronomic Chemotherapy for Metastatic Breast Cancer

Tumor endothelial cells as a potential target of metronomic chemotherapy

Metronomic Chemotherapy in Oral Cancer: A Review

Nanoparticle-mediated metronomic chemotherapy in cancer: A paradigm of precision and persistence

Synergy Between Low Dose Metronomic Chemotherapy and the pH-centered Approach Against Cancer

Dose-dependent bidirectional pharmacological effects of vinorelbine-based metronomic combination chemotherapy on tumor growth and metastasis and mechanisms in melanoma mouse model

The future of metronomic chemotherapy: experimental and computational approaches of drug repurposing

Promotion of tumor angiogenesis and growth induced by low-dose antineoplastic agents via bone-marrow-derived cells in tumor tissues

Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers